Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer

Completed · Phase 1

Conditions studied: Lung Cancer

In brief

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy and sargramostim in treating patients who have non-small cell lung cancer.

Key facts

Study ID

NCT00005630

Run by

Memorial Sloan Kettering Cancer Center

Starts

1999-07-01

Expected to finish

2002-05-01

Last updated by the study team

2013-06-19

Who can join

Age: 17 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.